SGRYSurgery Partners, Inc.

$14.04

SGRY as reported

Surgery Partners, Inc. reported $3.37B of revenue over the trailing twelve months, +4.0% on the year before. 11 reported series are charted on this page, each one as filed.

$3.37B

Revenue, trailing twelve months · to Q2 2026 · +4.0% against the twelve months before

Net Income
−$89M

Net Income · −51% year on year · trailing twelve months to Q2 2026

Free Cash Flow
$188M

Free Cash Flow · +7.0% year on year · trailing twelve months to Q2 2026

Op Margin
11%

Op Margin · trailing twelve months to Q2 2026

Every series Ryufin has for SGRY, trailing twelve months
SeriesLatestYear on yearAs of
Revenue$3.37B+4.0%Q2 2026
Net Income−$89M−51%Q2 2026
EPS−$0.69−52%Q2 2026
Gross Margin23%n/aQ4 2019 · 26 quarters behind
Op Margin11%n/aQ2 2026
Net Margin−2.7%n/aQ2 2026
ROE−6.1%n/aQ2 2026
ROA−1.3%n/aQ2 2026
ROIC6.0%n/aQ2 2026
Free Cash Flow$188M+7.0%Q2 2026
P/E103n/aQ2 2017 · 36 quarters behind

Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.

Revenue & ProfitSurgery Partners, Inc. (SGRY)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com